Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized high-activity radioiodine dosimetry in metastatic differentiated thyroid cancer
2011-005248-81Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of iodine-131 in well-differentiated thyroid cancer (WDTC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Dec 2011; status: completed.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2011-005248-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005248-81.